Steve J. Hodges

Nonagen Bioscience Corp. is a privately held biotechnology company that focuses on reducing the burden of cancer with innovative diagnostics. The company is currently seeking US Food and Drug Administration approval for Oncuria as an in vitro diagnostic test. The company is based in Los Angeles, CA. The company is committed to bringing best-in-class, noninvasive diagnostics for cancer detection, therapy choice, and disease monitoring to the market. Nonagen's lead diagnostic for bladder cancer, Oncuria®, is available as a laboratory developed test through Diacarta Laboratories. The company is developing diagnostics for bladder, breast, and prostate cancers. Nonagen Bioscience is physician-led and was founded in 2011. The company was founded in 2011 by Charles Joel Rosser, who has been the CEO since then.

Nonagen Bioscience Corp. is a privately held biotechnology company that focuses on reducing the burden of cancer with innovative diagnostics. The company is currently seeking US Food and Drug Administration approval for Oncuria as an in vitro diagnostic test. The company is based in Los Angeles, CA. The company is committed to bringing best-in-class, noninvasive diagnostics for cancer detection, therapy choice, and disease monitoring to the market. Nonagen's lead diagnostic for bladder cancer, Oncuria®, is available as a laboratory developed test through Diacarta Laboratories. The company is developing diagnostics for bladder, breast, and prostate cancers. Nonagen Bioscience is physician-led and was founded in 2011. The company was founded in 2011 by Charles Joel Rosser, who has been the CEO since then.

Nonagen Bioscience Corp. is a privately held biotechnology company that focuses on reducing the burden of cancer with innovative diagnostics. The company is currently seeking US Food and Drug Administration approval for Oncuria as an in vitro diagnostic test. The company is based in Los Angeles, CA. The company is committed to bringing best-in-class, noninvasive diagnostics for cancer detection, therapy choice, and disease monitoring to the market. Nonagen's lead diagnostic for bladder cancer, Oncuria®, is available as a laboratory developed test through Diacarta Laboratories. The company is developing diagnostics for bladder, breast, and prostate cancers. Nonagen Bioscience is physician-led and was founded in 2011. The company was founded in 2011 by Charles Joel Rosser, who has been the CEO since then.

Nonagen Bioscience Corp. is a privately held biotechnology company that focuses on reducing the burden of cancer with innovative diagnostics. The company is currently seeking US Food and Drug Administration approval for Oncuria as an in vitro diagnostic test. The company is based in Los Angeles, CA. The company is committed to bringing best-in-class, noninvasive diagnostics for cancer detection, therapy choice, and disease monitoring to the market. Nonagen's lead diagnostic for bladder cancer, Oncuria®, is available as a laboratory developed test through Diacarta Laboratories. The company is developing diagnostics for bladder, breast, and prostate cancers. Nonagen Bioscience is physician-led and was founded in 2011. The company was founded in 2011 by Charles Joel Rosser, who has been the CEO since then.